Research programme: neuregulins - Minerva Neurosciences

Drug Profile

Research programme: neuregulins - Minerva Neurosciences

Alternative Names: CNS growth factors - Mind-NRG; MIN 301; NRG-101

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator ProteoSys
  • Developer Minerva Neurosciences; ProteoSys
  • Class Neuregulins
  • Mechanism of Action Nerve growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 14 Mar 2016 Minerva Neurosciences has patents pending for MIN 301 in US, Japan, Brazil, Canada, Mexico and China (Minerva Neurosciences 10-k, March 2016).
  • 14 Mar 2016 Minerva Neurosciences has patent protection for MIN 301 in Europe, Australia, Russia and Japan (Minerva Neurosciences 10-k, March 2016)
  • 05 Jan 2015 Efficacy data from a Primomed preclinical trial in Parkinson's disease released by Minerva Neurosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top